Ausdal Financial Partners, Inc. Adaptimmune Therapeutics PLC Transaction History
Ausdal Financial Partners, Inc.
- $1.36 Billion
- Q2 2025
A detailed history of Ausdal Financial Partners, Inc. transactions in Adaptimmune Therapeutics PLC stock. As of the latest transaction made, Ausdal Financial Partners, Inc. holds 12,476 shares of ADAP stock, worth $623. This represents 0.0% of its overall portfolio holdings.
Number of Shares
12,476
Previous 12,476
-0.0%
Holding current value
$623
Previous $2,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding ADAP
# of Institutions
69Shares Held
116MCall Options Held
10.3KPut Options Held
0-
Eco R1 Capital, LLC San Francisco, CA27.4MShares$1.37 Million0.57% of portfolio
-
Long Focus Capital Management, LLC San Juan, PR23.8MShares$1.19 Million0.26% of portfolio
-
Two Seas Capital LP Rye, NY22.6MShares$1.13 Million0.1% of portfolio
-
Nea Management Company, LLC Timonium, MD17.1MShares$853,9880.34% of portfolio
-
Mpm Asset Management LLC Cambridge, MA4.81MShares$240,4832.66% of portfolio
About Adaptimmune Therapeutics PLC
- Ticker ADAP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 163,370,000
- Market Cap $8.17M
- Description
- Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...